euro adhoc: curasan AG
Restructuring & Recapitalisations
curasan
AG: increase in capital
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement.
23.05.2005
Kleinostheim, May 23, 2005 - curasan AG (WKN 549 453), a company specialising in regenerative medicine, has today placed 250,000 new ordinary shares, in the form of bearer shares, as part of an increase in capital decided upon by the Management Board on April 20, 2005, and authorised by the Supervisory Board on April 25, 2005. The capital increase of up to EUR 250,000, from currently EUR 5,000,000 to a maximum of EUR 5,250,000, was executed within the framework of existing Authorised Capital (so-called "Genehmigtes Kapital"). The subscription right of shareholders does not apply. The issue price of the new shares is EUR 1.91 per share. The new shares shall be entitled to dividends effective from January 1, 2005.
About curasan AG: curasan AG (ISIN: DE 000 549 453 8), an exchange-listed company, is a leading innovator within the growth market of bone and tissue regeneration. The company has developed a comprehensive product range centred around its synthetic bone regeneration material Cerasorb®, for use in soft and hard tissue. curasan AG's main goal is to occupy a leading position as a global specialist in Regenerative Medicine. For further information, please visit curasans corporate website at: www.curasan.de
End of ad hoc
end of announcement euro adhoc 23.05.2005 15:16:33
Further inquiry note:
Dr. Erwin Amashaufer, curasan AG, Tel. 06027/46 86 0, email:
ir@curasan.de
Branche: Biotechnology
ISIN: DE0005494538
WKN: 549453
Index: CDAX, Classic All Share, Prime Standard, Prime All Share
Börsen: Frankfurter Wertpapierbörse / regulated dealing
Berliner Wertpapierbörse / free trade
Hamburger Wertpapierbörse / free trade
Baden-Württembergische Wertpapierbörse / free trade
Börse Düsseldorf / free trade
Niedersächsische Börse zu Hannover / free trade
Bayerische Börse / free trade
Bremer Wertpapierbörse (BWB) / free trade
Original-Content von: Curasan AG, übermittelt durch news aktuell